安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B . . .
About Sonrotoclax (BGB-11417) Sonrotoclax is a next-generation and potentially best-in-class investigational B-cell lymphoma 2 (BCL2) inhibitor with a unique pharmacokinetic and pharmacodynamic profile
- Sonrotoclax Shows Promising Efficacy, Improved Tolerability in Heavily . . .
At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 inhibitor in heavily pretreated, largely refractory mantle cell lymphoma
- Sonrotoclax (BGB-11417) monotherapy in patients with Relapsed . . .
Sonrotoclax (BGB-11417), a next-generation B-cell lymphoma 2 (BCL2) inhibitor, is a more selective and pharmacologically potent inhibitor of BCL2 than venetoclax, with a shorter half-life and no drug accumulation
- Sonrotoclax - Wikipedia
Sonrotoclax is an investigational new drug that is being evaluated for the treatment of hematologic malignancies, particularly chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) [1]
- FDA Approves Sonrotoclax for Relapsed Refractory Mantle Cell Lymphoma
The FDA granted accelerated approval to sonrotoclax for relapsed refractory mantle cell lymphoma after at least 2 lines of systemic therapy
- Sonrotoclax Approval Delivers a Long-Awaited New Option for Relapsed or . . .
Sonrotoclax is a foundational, next-generation BCL2 inhibitor with a unique pharmacokinetic and pharmacodynamic profile According to the news release announcing its approval, sonrotoclax was proven in preclinical and clinical studies to be a highly potent and specific BCL2 inhibitor with a short half-life and no drug accumulation
- Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL
Today, the FDA granted accelerated approval to sonrotoclax (Beqalzi), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy,
- Sonrotoclax and Zanubrutinib as a Frontline CLL Treatment
The combination of sonrotoclax and zanubrutinib was well-tolerated and produced high rates of undetectable disease in patients with treatment-naïve CLL
|
|
|